- Home
- NTIP vs KPTI Comparison
NTIP vs KPTI Comparison
Compare NTIP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- KPTI
- Stock Information
- Founded
- NTIP 1990
- KPTI 2008
- Country
- NTIP United States
- KPTI United States
- Employees
- NTIP N/A
- KPTI N/A
- Industry
- NTIP Multi-Sector Companies
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- KPTI Health Care
- Exchange
- NTIP Nasdaq
- KPTI Nasdaq
- Market Cap
- NTIP 31.9M
- KPTI 33.6M
- IPO Year
- NTIP 1998
- KPTI 2013
- Fundamental
- Price
- NTIP $1.23
- KPTI $4.95
- Analyst Decision
- NTIP
- KPTI Strong Buy
- Analyst Count
- NTIP 0
- KPTI 5
- Target Price
- NTIP N/A
- KPTI $61.00
- AVG Volume (30 Days)
- NTIP 15.1K
- KPTI 161.4K
- Earning Date
- NTIP 05-09-2025
- KPTI 05-07-2025
- Dividend Yield
- NTIP 8.06%
- KPTI N/A
- EPS Growth
- NTIP N/A
- KPTI N/A
- EPS
- NTIP N/A
- KPTI N/A
- Revenue
- NTIP $100,000.00
- KPTI $145,237,000.00
- Revenue This Year
- NTIP N/A
- KPTI $4.87
- Revenue Next Year
- NTIP N/A
- KPTI $16.29
- P/E Ratio
- NTIP N/A
- KPTI N/A
- Revenue Growth
- NTIP N/A
- KPTI N/A
- 52 Week Low
- NTIP $1.17
- KPTI $3.51
- 52 Week High
- NTIP $2.07
- KPTI $21.30
- Technical
- Relative Strength Index (RSI)
- NTIP 40.54
- KPTI 48.29
- Support Level
- NTIP $1.20
- KPTI $3.83
- Resistance Level
- NTIP $1.28
- KPTI $4.36
- Average True Range (ATR)
- NTIP 0.06
- KPTI 0.43
- MACD
- NTIP -0.00
- KPTI 0.22
- Stochastic Oscillator
- NTIP 27.27
- KPTI 91.72
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.